shutterstock_1816265087_michael_vi

Michael Vi / Shutterstock.com

29 September 2020AmericasMuireann Bolger

Janssen sues Mylan to block generic of schizophrenia drug

A Johnson & Johnson (J&J) company, Janssen Pharmaceuticals, is seeking a court order blocking Mylan from making copies of its schizophrenia treatment, Invega Trinza, until its patent expires in 2036.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Janssen acquires anti-depressant drug in $25m deal

17 August 2017 Janssen, a subsidiary of Johnson & Johnson, has acquired an anti-depressant drug candidate in a $25 million deal with Cerecor.

Janssen sells five drugs for $155m

12 October 2016 India-based Piramal Enterprises has signed an agreement with Belgian pharmaceutical company Janssen under which Piramal will acquire five anaesthesia and pain management products for $155 million in cash.

Mylan asks SCOTUS to end NHK-Fintiv rule

16 August 2021 Mylan Laboratories has urged the US Supreme Court to overturn the controversial NHK-Fintiv rule, claiming that it is “unlawful”.

More on this story

Janssen acquires anti-depressant drug in $25m deal

17 August 2017 Janssen, a subsidiary of Johnson & Johnson, has acquired an anti-depressant drug candidate in a $25 million deal with Cerecor.

Janssen sells five drugs for $155m

12 October 2016 India-based Piramal Enterprises has signed an agreement with Belgian pharmaceutical company Janssen under which Piramal will acquire five anaesthesia and pain management products for $155 million in cash.

Mylan asks SCOTUS to end NHK-Fintiv rule

16 August 2021 Mylan Laboratories has urged the US Supreme Court to overturn the controversial NHK-Fintiv rule, claiming that it is “unlawful”.

More on this story

Janssen acquires anti-depressant drug in $25m deal

17 August 2017 Janssen, a subsidiary of Johnson & Johnson, has acquired an anti-depressant drug candidate in a $25 million deal with Cerecor.

Janssen sells five drugs for $155m

12 October 2016 India-based Piramal Enterprises has signed an agreement with Belgian pharmaceutical company Janssen under which Piramal will acquire five anaesthesia and pain management products for $155 million in cash.

Mylan asks SCOTUS to end NHK-Fintiv rule

16 August 2021 Mylan Laboratories has urged the US Supreme Court to overturn the controversial NHK-Fintiv rule, claiming that it is “unlawful”.

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB

Lewis Roca promotes tech expert to managing partner

Panitch Schwarze brings in molecular biologist

US targets ‘product hopping’ with biologic litigation curbs

UPC confirms validity of Edwards Lifesciences heart valve tech patent

ITC concludes row over biotech lab equipment between US and German rivals

UKIPO launches ‘revolutionary’ patent filing and AI tool

USPTO clarifies AI's role in patent eligibility